TNFRSF8 and enteropathy-associated T-cell lymphoma: While EATL was not a primary focus of ECHELON-2, global, randomized, double blind, phase III registrational trial designed to evaluate the efficacy and safety of BV + CHP in patients with CD30-positive PTCLs, the rationale for extrapolating BV + CHP to EATL includes proven better overall response rate (ORR), PFS and OS in all CD30 + PTCLs and based on this trial, NCCN guidelines now include BV + CHP for CD30 + PTCLs, which can encompass CD30 + EATL [17].